Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Biotechnology

Healthcare
$28.46 +3.66%

+$0.61 today

Market cap
$4.61B
Beta
2.15
P/E (TTM)
-54.5
EPS (TTM)
-$0.32
52W Low $9.96High $20.76

Volume 2.21M

Average 1.94M

ADPT Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

Adaptive Biotechnologies CorporationNASDAQ: ADPT

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin widens to 71.2%

Gross margin was 71.2% in Q2 FY2026, up 1.8 pp from a year earlier. On a trailing-twelve-month basis it was 75.4%, up 9.4 pp year over year. Over 3 fiscal years it widened by 5.5 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the highest level in the 4 fiscal years shown.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
71.2%-2.4 pp QoQ
Last fiscal yearDec 2025
74.2%+14.5 pp YoY
LTMJun 2026
75.4%+9.4 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+1.8 pp——
1 year+14.5 pp——
3 years+5.5 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
74.2%
Year-over-year change
+14.5pp

Gross Margin vs competitors

How ADPT compares with its peers on the latest reported figures

  • ADPT's LTM Jun 2026 gross margin of 75.4% is the 3rd highest of the 8 companies compared; the peer median is 56.5%.
  • Its year-over-year change of +9.4 pp is the 2nd highest of 7, against a peer median of -3.7 pp.
  • Over three fiscal years its change of +5.5 pp compares with a peer median of +1.6 pp.
ADPT Competitors Peer median
Gross Margin for ADPT and competitors
Company Period LTM level YoY 3-year change
BEAMBeam Therapeutics Inc.LTM Jun 2026100.0% +0.0 pp+495.5 pp
CPRXCatalyst Pharmaceuticals, Inc.LTM Mar 202682.3% -3.8 pp+1.2 pp
ADPTAdaptive Biotechnologies CorporationLTM Jun 202675.4% +9.4 pp+5.5 pp
LEGNLegend Biotech CorporationLTM Sep 202657.0% -3.6 pp+16.2 pp
ZLABZai Lab LimitedLTM Jun 202656.5% -5.9 pp-7.1 pp
TARSTarsus Pharmaceuticals, Inc.LTM Sep 20260.5% -88.3 pp-3.1 pp
IDYAIDEAYA Biosciences, Inc.LTM Mar 2026-8.7% +943.2 pp+2.0 pp
SRRKScholar Rock Holding CorporationLTM Sep 2026-8236.0% ——
IRONDisc Medicine, Inc.FY2025— ——
MLYSMineralys Therapeutics, Inc.FY2025— ——
Peer median (excluding ADPT) 56.5%-3.7 pp+1.6 pp

Competitors are the stored peer set for ADPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue154.34M185.31M170.28M178.96M276.98M
Cost of Revenue49.3M57.91M75.55M72.08M71.36M
Gross Profit105.04M127.4M94.72M106.88M205.62M
Gross Margin68.1%68.7%55.6%59.7%74.2%
Research & Development142.34M141.76M122.12M102.95M93.77M
Selling, General & Admin169.97M184.13M172.51M157.57M167.27M
Operating Expenses314.01M327.59M321.76M269.43M262.74M
Depreciation & Amortization13.95M20.92M22.23M19.26M17.83M
EBITDA(193.35M)(175.21M)(189.27M)(128.76M)(29.85M)
EBITDA Margin-125.3%-94.6%-111.2%-71.9%-10.8%
Operating Income(208.97M)(200.19M)(227.04M)(162.55M)(57.12M)
Operating Margin-135.4%-108.0%-133.3%-90.8%-20.6%
Interest Income1.67M4.06M15.53M14.53M9.44M
Interest Expense04.24M13.8M11.58M11.78M
Other Income / Expenses1.67M(182K)1.73M2.95M(2.33M)
Income Before Tax(207.3M)(200.37M)(225.3M)(159.6M)(59.46M)
Pre-Tax Margin-134.3%-108.1%-132.3%-89.2%-21.5%
Income Tax Expense00000
Net Income(207.28M)(200.19M)(225.25M)(159.49M)(59.5M)
Net Margin-134.3%-108.0%-132.3%-89.1%-21.5%
EPS (Basic)(1.46)(1.00)(1.56)(1.08)(0.39)
EPS (Diluted)(1.46)(1.00)(1.56)(1.08)(0.39)
Weighted Avg Shares140.35M142.52M144.38M147.1M151.72M
Weighted Avg Shares (Diluted)140.35M142.52M144.38M147.1M151.72M

Adaptive Biotechnologies Corporation

NASDAQ:ADPT

Intrinsic Alpha fair value

Locked

Current Price

$28.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.